Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARR 17477

Drug Profile

ARR 17477

Alternative Names: ARL 17477

Latest Information Update: 22 Jan 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astra Arcus USA; AstraZeneca R&D Charnwood
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Pain; Stroke

Most Recent Events

  • 15 Feb 2000 A study using a severe model of permanent focal cerebral ischaemia has been added to the pharmacodynamics section
  • 21 Dec 1999 A study has been added to the pharmacodynamics section
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top